House Resolution 444 is a commemorative resolution declaring October 13, 2025, as Metastatic Breast Cancer Awareness Day in Illinois. The resolution explains that breast cancer remains a major public health issue, highlights the severity of metastatic breast cancer (MBC), and notes that MBC is the stage of the disease that occurs when cancer spreads beyond the breast to other organs. It also emphasizes that MBC has no known cure, has a poor median life expectancy, and receives a relatively small share of breast cancer research funding.
The resolution further recognizes METAvivor Research and Support and the #LightUpMBC campaign, which uses teal, green, and pink to raise awareness and honor those affected by MBC. It calls attention to racial disparities in breast cancer outcomes, including higher mortality rates for Black women and the disease’s impact on Hispanic women, and frames increased research, education, and access to care as necessary responses. The measure encourages residents to support awareness efforts and local landmark lightings, but it does not create a regulatory program or funding mandate.
Impact
HR0444 does not amend the Illinois Compiled Statutes or create enforceable legal requirements. Its legal effect is symbolic: it establishes a statewide awareness day and encourages public participation in awareness activities, including landmark illumination and support for metastatic breast cancer research. The resolution may help elevate public attention to MBC, patient advocacy, and disparities in cancer outcomes, but it does not directly change benefits, health coverage, or research appropriations.
Sentiment
The overall sentiment of the resolution is strongly supportive and commemorative. The bill’s findings present metastatic breast cancer as an urgent and under-recognized health issue and express sympathy for patients and families affected by the disease. Because the measure is a resolution honoring awareness rather than a policy bill, it appears designed to generate consensus around public recognition and advocacy rather than partisan debate.
Contention
No committee transcript or vote history is available, and the bill text itself contains no explicit opposition. The only potentially contentious policy theme is the resolution’s emphasis on the gap between current breast cancer research funding and the amount advocates believe should be directed to metastatic breast cancer, as well as its focus on racial disparities in outcomes. However, the measure does not propose a funding formula or enforcement mechanism, so any disagreement would likely be about broader cancer research priorities rather than the resolution’s commemorative designation.